Novelties in the field of anti-infectives in 1997

Clinical Infectious Diseases

Volumn 27, Issue 4, 1998, Pages 865-883

  Bryskier, André ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CEFTIZOXIME ALAPIVOXIL; CEPHALOSPORIN DERIVATIVE; ECENOFLOXACIN; ERYTHRONOLIDE A; GARENOXACIN; GATIFLOXACIN; GM 237354; HMR 3004; KETOLIDE; KRQ 10018; KRQ 10071; KRQ 10196; KST 150257; KST 150290; MACROLIDE; MOXIFLOXACIN; PGE 711699; PGE 7594630; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SYN 2190; TE 802; TEA 0769; TELITHROMYCIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WQ 2724; WQ 2743;

ANTIBIOTIC THERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 2442735449     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514929     Document Type: Review

References (115)

1. Bryskier A. Novelties in the field of fluoroquinolones. Expert Opin Invest Drugs 1997; 6:1227-45.
2. Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Expert Opin Invest Drugs 1994; 3:145-71.
3. Bryskier A. Novelties in the field of patenteral cephem antibacterials since 1993. Expert Opin Invest Drugs 1997; 6:305-20.
4. Bryskier A. Novelties in the field of macrolides. Expert Opin Invest Drugs 1997; 6:1697-709.
5. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Design 1996; 2:175-94.
6. Bryskier A. Dual β-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin Invest Drugs 1997; 6:1479-99.
7. Turner WW, Rodriguez MJ. Recent advances in the medicinal chemistry of antifungal agents. Curr Pharm Design 1996; 2:209-24.
8. Takashima K, Oki T. Azole antifungal agents. Expert Opin Ther Patents 1996; 6:645-54.
9. Lee Y, Kim DH, Hwan JY, et al. Pharmacokinetics (PK) and safety of CFC-222 in healthy volunteers [abstract F-171]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:175.
10. Hayashi K, Todo Y, Hamamoto S, et al. T-3811, a novel des-F(6)-quinolone: synthesis and in vitro activity of 7-(isoindolin-5-yl) derivatives [abstract F-158]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
11. Takahata M, Misuyama J, Yamashiro Y, et al. T-3811, a novel des-F(6)-quinolone: in vitro and in vivo antimicrobial activities [abstract F-159]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
12. Takahata M, Misuyama F, Yamashiro Y, et al. T-3811, a novel des-F(6)-quinolone: study of pharmacokinetics in animals [abstract F-160]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
13. Fuhurata K, Soumi K, Matsumot J, et al. T-3811, a novel des-F(6)-quinolone: comparative studies of the adverse reactions associated with quinolones [abstract F-161]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
14. Nagai A, Takahata M, Miyazaki M, et al. T-3811, a novel des-F(6)-quinolone: toxicological evaluation [abstract F-162]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
15. Amano H, Hayashi N, Oshita Y, Nino Y, Yazaki A, WQ 2724 and WQ 2743, novel fluoroquinolones: in vitro and in vivo activities, pharmacokinetics and toxicity [abstract F-163]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:173.
16. Oshita Y, Yazaki A. In vitro studies with WQ-3034, a newly synthesized acidic fluoroquinolone [abstract F-164]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:174.
17. Park TH, Nam KS, Ha YH, et al. Synthesis and antibacterial activity of KRQ 10,018 and its analogues: potent DNA gyrase inhibitors [abstract F-173]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:175.
18. Barry AL, Brown SD, Fuchs PC. Antipneumococcal activity of a ketolide (HMR 3647) and seven related drugs in vitro [abstract F-107]. In: Program and abstracts of the 37th Interscience Conference on Antimi-crobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:164.
19. Negri MC, Morosini MI, Loza E, Meseguer MA, Almaraz F, Baquero F. The novel ketolide HMR 3647 is highly active on antibiotic susceptible and resistant Streptococcus pneumoniae [abstract F-110]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:164.
20. Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity (MIC) of HMR 3647 (RU 66647), a new ketolide, compared to 16 other agents [abstract F-108]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:164.
21. Rosato A, Vicarini H, Bonnefoy A, Chantot JF, Leclercq R. A non-inducer ketolide, HMR 3004 (RU 64004), active against streptococci inducibly cross-resistant to macrolides and lincomycin [abstract C-70]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:58.
22. Bryskier A, Agouridas C, Chantot JF. Ketolides: new semi-synthetic 14-membered-ring macrolides. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. Expanding indications for the new macrolides, azalides and streptogramins. New York: Marcel Dekker, 1997:39-50.
23. Wise R, Andrews JM. The in vitro activity of a new ketolide HMR 3647 against a wide range of clinical isolates [abstract F-114]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:165.
24. Labro MT, Vazifeh D, Abdelghaffar H. Effect of the new ketolide HMR 3647 on human neutrophil (PMN) function in vitro [abstract F-256]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
25. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM. Susceptibility of Legionella spp. to ketolide HMR 3647 and other newer antimicrobials [abstract F-250]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
26. Smith RP, Baltch AL, Ritz W, Franke M, Michelsen P. Antibacterial effects of ketolides HMR 3004 and HMR 3647 against intracellular Legionella pneumophila (L.pn) [abstract F-249]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
27. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae [abstract F-248]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
28. Felmingham D, Robbins MJ, Leakey A, et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates [abstract F-116]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:166.
29. Wexler HM, Molitoris E, Finegold SM. In vitro activity of HMR 3647 (RU 66647) against 512 strains of anaerobic bacteria [abstract F-120]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:166.
30. Reig M, Moreno A, Baquero F. Activity of the new ketolide, HMR 3647, against anaerobic bacteria [abstract F-121]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:166.
31. Ednie L, Jacobs M, Appelbaum P. Antianaerobic activity of the ketolide HMR 3647 (RU 66647) compared to 12 other compounds [abstract F-122]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:167.
32. Visalli MA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of HMR 3647 (RU 6647), a new ketolide, compared to other drugs, by time-kill [abstract F-109]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:164.
33. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, demonstrated by studies of time-kill kinetics and postantibiotic effect [abstract F-254]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
34. Jacobs MR, Bajaksouzian S, Chuang J, Ronchetti MR, Appelbaum PC. Postantibiotic effect of the ketolide HMR 3647 (RU 6647) on Grampositive cocci [abstract F-253]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
35. Soriano F, Calvo R, Fernandez-Roblas R. In vitro activity of ketolide HMR 3647 (RU 66647) against gram-positive bacilli [abstract F-118]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:166.
36. Martiñez-Martiñez L, Pascual A, Suarez AI, Perea EJ. In vitro activities of ketolide HMR 3647, five macrolides, and clindamycin against coryneform bacteria isolated from clinical samples [abstract F-246]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:187.
37. Torres C, Zarazaga M, Tenorio C, Saenz Y, Portillo A, Baquero F. Susceptibility of Lactobacillus, Leuconostoc and Pediococcus to ketolide HMR 3647 and other antibiotics [abstract F-247]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
38. Engler KH, Warner M, George RC. In vitro susceptibility of Corynebacterium diphtheriae to a new macrolide, HMR 3647 [abstract F-124]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:167.
39. Hoban D, Karlowsky J, Weshnoweski B, Kabani A, Zhanel G. In vitro activity of a new ketolide HMR 3647 against geographically diverse Canadian isolates of Enterococcus spp. [abstract F-119]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:166.
40. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM. Susceptibility of Legionella spp. to ketolide HMR 3647 and other newer antimicrobials [abstract F-250]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
41. Kitzis MD, Goldstein FW, Bismuth R, Meigi M, Acar JF. Comparative in vitro activity of HMR 3647, a new ketolide antibiotic, against S. aureus (SA) and coagulase negative staphylococci (CNS) [abstract F-111]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:165.
42. Rajagopalan-Levasseur P, Vallée E, Agouridas C, et al. HMR 3647: activity against erythromycin-resistant pneumococci and Haemophilus influenzae in murine pneumonia models [abstract F-260]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:190.
43. Vesga O, Craig WA, Bonnat C. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [abstract F-255]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
44. Vesga O, Andes D, Craig WA. Comparative in vivo activity of HMR 3647, azithromycin (AZI), clarithromycin (CLA) and roxithromycin (ROX) against S. pneumoniae (SP) and S. aureus (SA) [abstract F-258]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
45. Vesga O, Craig WA. Impact of macrolide resistance on the in vivo activity of a new ketolide, HMR 3647, against S. pneumoniae (SP) and S. aureus (SA) [abstract F-259]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:189.
46. Malathum K, Coque T, Singh KV, Murray BE. Studies of a new ketolide, HMR 3647, against multi-resistant gram-positive cocci [abstract F-115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:165.
47. Araujo FG, Khan AA, Bryskier A, Remington JS. Ketolides are active against Toxoplasma gondii [abstract F-251]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:188.
48. Wu M, Kolonoski P, Bermudez LE, Young LS. Efficacy of two ketolides, HMR 3004 and HMR 3647, in treatment of disseminated M. avium (MAC) disease in beige mice [abstract F-261]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:190.
49. Goldstein EJC, Citron DM, Gerardo SH, Hudspeth M, Merriam CV. Comparative in vitro activity of HMR 3004 (HMR), a new ketolide, with azithromycin, clarithromycin, roxithromycin and erythromycin against 311 aerobic and anaerobic bacteria isolated from human and animal bite wound infection [abstract F-123]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:167.
50. Asaka T, Kashimura M, Misawa Y, et al. A new macrolide antibiotic, TE-810, synthesis and biological properties [abstract F-177]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:144.
51. Asaka T, Kashimura M, Misawa Y, et al. A new macrolide antibiotic, TE-802, synthesis and biological properties [abstract F-176]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:143.
52. Phan LY, Or YS, Spina KP, et al. Tricyclic ketolides: mono-substitution on the imine ring. Synthesis and in vitro antibacterial activity [abstract F-263]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:190.
53. Phan LYT, Or YS, Chen Y, et al. Tetracyclic ketolides: new antibacterial macrolides-synthesis and in vitro antibacterial activity [abstract F-264]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:190.
54. Asaka T, Kashimura M, Tanikawa T, et al. New macrolide antibiotics, acylides (3-0-acyl-5-0-desosaminylerythronolides): synthesis and biological properties [abstract F-262]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:190.
55. Griesgraber G, Elliott R, Mark J, et al. Synthesis and in vitro activity of novel 2,3-anhydro-11-hydrazo-6-0-methyl-11,12-carbamate erythromycin derivatives [abstract F-267]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:191.
56. Elliot RI, Pireh D, Griesgraber G, et al. Synthesis and in vitro activity of novel 2,3-anhydro-6-0-methyl-11,12 carbamate erythromycin analogues [abstract F-265]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:191.
57. Labro MT, Abdelghaffar H, Kirst H. Structure-activity relationships among erythromycylamine (ECM) derivatives for their effects on human neutrophils (PMN) in vitro [abstract F-268]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:191.
58. Gadwood RC, Kamdar BV, Sims SM, Martin IJ, Zurenko GE, Ford CW. Synthesis of oxazolidinone antibacterial agents incorporating morpholine and piperazine N-oxides: oxazolidinone prodrugs having high water solubility [abstract F-20]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
59. Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Potent water soluble prodrugs of the oxazolidinone antibacterial agent eperezolid [abstract F-23]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:150.
60. Ulanowicz DA, Brickner SJ, Ford CW, Zurenko GE. Synthesis and biological activity of N-acetyl modified analogs of oxazolidinone antibacterial agents linezolid and eperezolid [abstract F-21]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
61. Poel TJ, Thomas RC, Ford CW, Zurenko GE. Novel phenyloxazolidinone antibacterial agents containing saturated and 4,5-unsaturated 4-pyridinyl, pyranyl and thiopyranyl aryl substituents [abstract F-22]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
62. Bartel S, Endermann R, Guarnieri W, et al. Synthesis and antibacterial activity of novel hereroaryl oxazolidinones I: thiophenyl oxazolidinones [abstract F-17]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
63. Bartel S, Endermann R, Guarnieri W, et al. Synthesis and antibacterial activity of novel heteroxyl oxazolidinones II: pyridyl oxazolidinones [abstract F-18]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
64. Bartel S, Endermann R, Guarnieri W, et al. Synthesis and antibacterial activity of novel heteroxyl oxazolidinones III: activities against clinically important gram-positive cocci [abstract F-19]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:149.
65. Glinka T, Cho IS, Zhang JS, et al. Discovery of MC-02,479 and analogs, new cephalosporins active against resistant gram-positive bacteria [abstract F-176]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:176.
66. Malouin F, Chan C, Bond S, Chamberland S, Lee VJ. In vitro inhibitory activity of a new cephalosporin (MC-02,479) against multi-resistant gram-positive bacteria [abstract F-177]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:176.
67. Blais J, Malouin F, Mathias K, Chan C, Chamberland S, Lee VJ. Bactericidal activity and postantibiotic effect (PAE) of MC-02,479, a new cephalosporin with potent activity against multi-resistant gram-positive bacteria [abstract F-179]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:176.
68. Griffith D, Annamalai T, Bond SM, Harford L, Williams R, Lee VJ. Efficacy of MC-02,479, a new cephalosporin, in the treatment of experimental murine infections due to gram-positive bacteria [abstract F-180]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:176.
69. Chamberland S, Chan C, Biais J, Mathias M, Malouin F, Lee VJ. MC-02,479, a new cephalosporin with high affinity for PBP2a and stability to staphylococci β-lactamases [abstract F-178]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:176.
70. Annamalai T, Griffith D, Bond SM, et al. Pharmacodynamics (PD) of MC-02,479 in murine thigh models of infection due to methicillin-resistant Staphylococcus aureus (MRSA) [abstract F-181]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:177.
71. Choi KI, Cha JH, Cho YS, et al. Novel 3-isoxazolylvmylcephalosporins: I-synthesis and in vitro antimicrobial susceptibilities [abstract F-182]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:177.
72. Park SH, Park SY, Kim DY, et al. Novel 3-isoxazolyl vinyl cephalosporins. II. Antibacterial activities against clinical isolates and pharmacokinetics in mice [abstract F-183]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:177.
73. Livermore DM, Babini GS. SYN-2190/β-lactam combinations vs. P. aeruginosa strains with denned resistance mechanisms [abstract F-191]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:178.
74. Maiti SN, Phillips OA, Setti EL, et al. SYN-2190: synthesis and structure-activity relationships of a novel series of 2-oxo-1-azetidine sulfonic acids as potent β-lactamase inhibitors [abstract F-188]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:178.
75. Weiss WJ, Mikels SM, Jacobus NV, Lin F, Testa RT. In vivo activity of peptidic prodrugs of novel aminomethyl THF 1β-methylcarbapenems [abstract F-221]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:184.
76. Snyder NJ, Zweifel MJ, Cooper RDG, et al. New semisynthetic glycopeptide amides active against resistant enterococci [abstract F-2]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:146.
77. Steinberg DA, Hurst MA, So W, Viajar BSC, Fuji CA. IB-367: a protegrin peptide with rapid microbicidal activity against the flora associated with oral mucositis [abstract F-48]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:154.
78. Coleman MS, Rabe LK, Hillier SL. In vitro activity of an antimicrobial peptide for use as a vaginal microbicide [abstract F-44]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:153.
79. Fuchs PC, Barry AL, Brown SD. In vitro antimicrobial activity and spectrum of the topical peptide [abstract F-46]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:153.
80. Harris LM, Anderson SW, Cihle N, et al. Activity of bicyclic nitroimidazopyran compounds, including PA-824 against Helicobacter pylori [abstract F-26]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:150.
81. Anderson SW, Arain TM, Sherman DR. In vitro antimycobacterial activity of the nitroimidazopyran compound, PA-824, under low oxygen conditions [abstract F-25]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:150.
82. Richtchie HD, Orta GJ, Harris LM, Adams PC, Nywall CS, Arain TM. Toxicology and toxicokinetics of PA-824 and PA-1,297, two nitroimidazopyran antitubercular agents in mice [abstract F-27]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:150.
83. Ma Z, Chu DTW, Li Q, et al. Antibacterial 2-pyridones: consequence of structural modifications at the C-8 position [abstract F-169]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:174.
84. White RE, Gasparski CM, Kim ND, et al. Synthesis and biological evaluation of quinolonyl-carbacephalosporin antibacterials [abstract F-193]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:179.
85. Kraft WG, Leunk RD, McKeever HD, et al. In vitro activity of quinolonyl-cephem amines [abstract F-195]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:179.
86. Vesga O, Craig WA. In vivo pharmacodynamic activity of SCH 27,899 5SCH (Ziracin) and everninomicin antibiotic [abstract A-32]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:6.
87. Banfield CR, Glue P, Affrime MP, et al. Multiple-dose safety, tolerance and pharmacokinetics of Ziracin (SCH 27,899): a new, novel oligosaccharide antibiotic [abstract A-114]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:23.
88. Menon S, Pai S, Banfield CR, Cayen M, Affrime MB, Batra V. Effect of gender on the pharmacokinetics of Ziracin (SCH 27,899) in healthy volunteers [abstract A-113]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:23.
89. Demers JP, Bernstein JI, Fernandez JA, et al. The identification of RWJ 49,815, a novel inhibitor of bacterial two component regulatory systems and a potent gram positive antibacterial [abstract F-227]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:185.
90. Licata L, Melton JL, Fernandez JA, et al. In vitro characterization of a novel class of antibacterial agents that inhibit bacterial two-component systems [abstract F-226]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:184.
91. Macielag MJ, Bernstein J, Demers JP, et al. Antibacterial salicylamides that inhibit bacterial two-component regulatory systems [abstract F-228]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:185.
92. Treiberg JA, Cai S, Towell JA, et al. Synthesis and antimycobacterial activity of novel nitroamidazopyrane [abstract F-24]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:150.
93. Cynamon M, Lang M, O'Railly T, Chmielewski A, Klemens S. In vitro and in vivo activities of new nitroimidazole derivatives against M. tuberculosis (MTB) [abstract F-30]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:151.
94. Suling WJ, Reynolds RC, Barrow EW, Wilson LN, Piper JR, Barrow WN. In vitro activity of lipophilic dihydrofolate reductase (DHFR) inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex [abstract F-42]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:153.
95. Onwuta US, Kanyok TP, Morgen FD. Extraction and antimycobacterial activity of an alkenyl resorcinol from Ardisia iwahigensis Elmer [abstract F-51]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:154.
96. Li L, Thomas DJ, Grampovnick L, et al. Synthesis and antifungal activities of cyclopeptamines. Novel cell wall synthesis inhibitors [abstract F-238]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:186.
97. Meulbroeck JA, Oleksijew A, Tovcimak A, et al. Efficacy of A-175, 800.0, an inhibitor of fungal cell wall synthesis, against experimental systemic candidiasis [abstract F-82]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:159.
98. Capobianco JA, Zakula D, Frost DJ, Goldman RG, Li L, Klein L, Lartey P. Cellular uptake, localization and activity of A 172,013, a synthetic cyclopentamine, in fungi [abstract F-83]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. 1997:160.
99. Bartroli J, Turmo E, Alguero M, et al. UR-9,825: a new triazole derivative with potent, broad-spectrum antifungal activity [abstract E-67]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:125.
100. Unno H, Kamei K, Honda A, et al. A munne model of invasive pulmonary basidiomycosis by Shizophyllum commune. Efficacy of SSY726 [abstract F-106]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:164.
101. Suzuki K, Ishii K, Iwayama S, et al. V28-3B methyl ester, a new polyene antifungal compound: in vitro and in vivo efficacy and safety [abstract F-89]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:161.
102. Falk R, Azzam T, Ehrenfreund T, Domband A, Polachek IS. Development of a novel injectable water-soluble amphotericin B-conjugate as an antifungal agent [abstract F-90]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:161.
103. Jessup CJ, Wallace TL, Ghannoum MA. Evaluation of antifungal activity of Nyotran against various pathogenic fungi [abstract F-88]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:161.
104. Bueno JM, Chicharro J, Huss SL, Fiandor JM, Gomez de las Heras F. Synthesis of the antifungal GM 237,354 [abstract F-54]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:155.
105. Dominguez JM, Capa L, Serramia MMJ, et al. Tranlation elongation factor 2 (EF2) is the target for sordarin-derived antifungals [abstract F-55]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:155.
106. Sanchez-Sousa A, Alvarez ME, Parra C, Baquero F. Activity on clinical
107. Aviles P, Pateman A, San Roman R, Gargallo D. Single dose pharmacokinetic studies in rodents with GM 237,354 [abstract F-66]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:157.
108. Takesako K, Awazu N, Yoshikawa Y, Koyama E, Kato I. Structure and properties of antifungal antibiotic TKR 1,785 having a sphingosine-like lipid moiety [abstract F-97]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:162.
109. Monti F, Ripamonti F, Hawser SP, Islam K. The antifungal compound aspirochlorine specifically inhibits fungal, but not mammalian or bacterial, protein synthesis [abstract F-98]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:162.
110. Ben-Josef AM, Manavathu EK, Platt D, Sobel DJ. Calcium-dependent fungicidal activity of CAN-296, a naturally occurring complex carbohydrate [abstract F-99]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:162.
111. Del Poeta M, Schell WA, Dykstra CC, Tidwell R, Boykin D, Perfect JR. The dicationic aromatic compounds: a new class of antifungal agents [abstract F-101]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:163.
112. Dei-Cas E, Aliouat EM, Mullet C, Mazars E, Gargallo D. A new antimicrobial molecule (GM 237,354) highly active against Pneumocystis carinii: in vivo studies and ultrastructural data [abstract F-65]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:157.
113. Bender BC, Hall JE, Tidwell RR, Boykin DW, Perfect JR, Kyle DE. Aromatic diamidoxime prodrugs active against Pneumocystis carinii [abstract F-100]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:163.
114. Bartlett MS, Mc Chesney JD, Shaw MM, Nanayakkara D, Durant PJ, Smith JW. The 8-aminoquinoline DN3 27-1 was effective for prophylaxis against Pneumocystis carinii in mice and rats [abstract F-174]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:175.
115. Dykstra CC, Hildebrandt EF, Tidwell RR, Hall JE, Boykin DW. Identification of a novel target for aromatic dicationic molecules from Pneumocystis carinii [abstract F-240]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:187.